This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
by Zacks Equity Research
Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.
BIIBPositive Net Change BAYRYNegative Net Change CRMDPositive Net Change DNLIPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for Aug 12, 2025
by Zacks Equity Research
Companies In The News Are: MU, AAON, LEGN, FNV.
MUPositive Net Change FNVNegative Net Change AAONNegative Net Change LEGNNegative Net Change
biotechnology construction gold semiconductor
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
by Ahan Chakraborty
LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral obesity pill.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pre-Markets in Green, Inflation Data, Retail Sales, Q2 Earnings This Week
by Zacks Equity Research
U.S. stock futures edged higher this morning after an impressive last week.
CENegative Net Change BPositive Net Change FNVNegative Net Change LEGNNegative Net Change MNDYNegative Net Change ACHRNegative Net Change OKLONegative Net Change
biotechnology finance gold internet
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
by Ekta Bagri
Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.
GILDNegative Net Change INOPositive Net Change DERMPositive Net Change ZVRANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for Aug 11, 2025
by Zacks Equity Research
Companies In The News Are: GILD, TTD, TXRH, GEN.
GILDNegative Net Change TXRHNegative Net Change GENNegative Net Change TTDNegative Net Change
biotechnology internet restaurants tech-stocks
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
by Zacks Equity Research
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
REGNNegative Net Change CRMDPositive Net Change NTLAPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings gene-therapy medical pharmaceuticals
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
HALONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Reddit Inc. (RDDT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
RDDTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up
by Zacks Equity Research
GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.
GSKNegative Net Change GILDNegative Net Change KYMRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
CPRXPositive Net Change CRMDPositive Net Change ARVNPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
CRMDPositive Net Change ACADPositive Net Change ARVNPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
RIGLPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy GeneDx Holdings Corp. (WGS) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
WGSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Piper Sandler Companies (PIPR) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PIPRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
CB Financial Services (CBFV) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
CBFVNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
by Zacks Equity Research
ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.
CRMDPositive Net Change ADMANegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles
by Zacks Equity Research
NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.
NVONegative Net Change LLYPositive Net Change ARVNPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.
CRMDPositive Net Change ARVNPositive Net Change IMCRPositive Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.
REGNNegative Net Change RAREPositive Net Change ARVNPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bayer Beats on Q2 Earnings and Sales, Raises '25 Adjusted Sales View
by Zacks Equity Research
BAYRY beats on Q2 earnings and raises 2025 sales outlook (on a currency-adjusted basis) as pharma growth offsets currency and Xarelto headwinds.
REGNNegative Net Change JNJPositive Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Tidewater (TDW)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
TDWPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Ekta Bagri
BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.
BMYNegative Net Change PFENegative Net Change BNTXNegative Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
Small-Caps Stay Higher, Other Indexes Dwindle
by Mark Vickery
President Trump mentioned adding new tariffs on semiconductor imports, which helped move markets aside from the Russell 2000 lower.
AMDNegative Net Change AMGNPositive Net Change SWKSNegative Net Change SMCIPositive Net Change SNAPNegative Net Change
biotechnology earnings semiconductor social-media
ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised
by Zacks Equity Research
Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.
ZTSNegative Net Change CRMDPositive Net Change ARVNPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals